Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs placebo in active peripheral spondyloarthritis (phase III)
2021-001256-34Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral spondyloarthritis (pSpA) comparing Secukinumab 300 mg with Placebo (2 arms). Primary endpoint: mPSpARC40 response at Week 16. Started Oct 2021; status: terminated.
02
Drugs
secukinumab
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on 2021-001256-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001256-34.